Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Karlsruhe – page 21

883 clinical trials in Karlsruhe, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Karlsruhe at a glance
883
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

883 trials in Karlsruhe

Open in trial search

Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HDP-101
  • Sponsor:Heidelberg Pharma AG

Study of Gilteritinib, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Not Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Neoplasm

Recruiting

Study on Treating Solid Tumors with Genetically Modified T-Cells (IMA203, IMA203CD8) and Nivolumab for Patients with Recurrent or Refractory Conditions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IMA203CD8
  • Sponsor:Immatics US Inc.

Study on the Effects of Cyclosporine A in Patients with Takotsubo Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Lymphangiosarcoma+34

Recruiting

Study of trabectedin alone versus trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ttf-Ngr
  • Sponsor:Universitaet Muenster

Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Uveal melanoma

Recruiting

Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Glioma

Recruiting

Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on CD19+ Lymphoid Disease Using Genetically Modified T Cells for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:HD-CAR-1
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University Of Cologne

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Karlsruhe

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on colorectal cancer, breast cancer, and various types of lymphomas. Studies evaluate novel combination therapies and targeted treatments for patients with different stages of disease.

  • Metastatic colorectal cancer treatments
  • Triple-negative breast cancer therapy
  • B-cell lymphoma interventions

Advanced trials exploring immunotherapy combinations and precision medicine approaches.

02 Hematologic Malignancies

Groundbreaking studies in acute myeloid leukemia and chronic lymphocytic leukemia, testing innovative drug combinations and targeted therapies.

  • Novel AML treatment combinations
  • CLL/SLL therapeutic approaches
  • Multiple myeloma interventions

Focus on improving survival rates through personalized treatment strategies.

03 Chronic Conditions

Research addressing chronic kidney disease, pulmonary diseases, and metabolic disorders. Studies evaluate new therapeutic options for managing long-term health conditions.

  • COPD treatment innovations
  • Kidney disease management
  • Sleep apnea interventions

Emphasis on improving quality of life and disease outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.